Urša Jenko
Osnovno zdravstvo Gorenjske, Zdravstveni dom Jesenice, Jesenice, Slovenija

Milica Stefanović
Klinični oddelek za otroško hematologijo in onkologijo, Pediatrična klinika, Univerzitetni klinični center Ljubljana, Slovenija

Barbara Faganel Kotnik
Klinični oddelek za otroško hematologijo in onkologijo, Pediatrična klinika, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija in Katedra za pediatrijo, Medicinska fakulteta, Univerza v Ljubljani, Ljubljana, Slovenija

Lidija Kitanovski
Klinični oddelek za otroško hematologijo in onkologijo, Pediatrična klinika, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija

Abstract

Low-grade gliomas (LGG) are the most common primary tumours in the central nervous system in children. Histologically, they are a heterogeneous group of brain tumours. The most common of them is pilocytic astrocytoma. The signalling pathway of mitogen-activated protein kinase (MAPK) is involved in the pathogenesis of these tumours, so the search for effective targeted drugs with few side effects is the subject of current research. This article presents a clinical case of a boy with inoperable LGG, which was poorly responsive to established systemic treatment, so he received targeted treatment with an MEK inhibitor.

Key words: low-grade gliomas, targeted therapy, MEK inhibitors, children